The anticipation of higher earnings and revenue for Goldman Sachs suggests a positive outlook, which could lead to a short-term increase in stock price. The recent closure of the Life Sciences I fund above its target also reflects positively on the company's asset management capabilities. However, the recent share price drop indicates some investor caution. The mixed analyst ratings and price target revisions, with some analysts raising and others lowering their targets, could create uncertainty, but the overall positive revisions suggest a bullish sentiment.